Click here to load reader

Childhood pneumonia: clinical features It is not possible to distinguish between bacterial and viral pneumonia on clinical grounds alone! Suggestive of

  • View
    219

  • Download
    3

Embed Size (px)

Text of Childhood pneumonia: clinical features It is not possible to distinguish between bacterial and viral...

  • Slide 1
  • Childhood pneumonia: clinical features It is not possible to distinguish between bacterial and viral pneumonia on clinical grounds alone! Suggestive of bacteria: Rapid onset (tachypnea, cough, retractions) Likely to appear very sick Higher temperatures (>39 C) Suggestive of virus: Low-grade fever, irritable but not toxic (usually!) Associated complaints: HA, sore throat, myalgias, GI complaints Longer prodrome (2-3 days or longer) Concomitant URI symptoms at times
  • Slide 2
  • Indications for hospitalization in pediatric pneumonia Considered for most infants 70 breaths/min in infanst 50 breaths/min in older children, difficulty breathing, apnea, grunting Toxic appearance (tends to be more common with bacterial etiologies) Underlying conditions predisposing to a more serious course (cardiopulmonary disease, immunocompromised, metabolic disorders) Presence of complications effusions/empyema Failure of outpatient therapy (worsening or no response in 24-72 hours)
  • Slide 3
  • Indications for treatment in an intensive care unit in pediatric pneumonia Failure to maintain O2 saturation >92% in FiO2 >0.5-0.6 Signs of impending respiratory failure (lethargy, increasing work of breathing, and/or fatigue with or without hypercarbia) Recurrent apneic episodes or slow, irregular respirations Cardiovascular compromise with progressive tachycardia and/or hypotension
  • Slide 4
  • Pediatric Community-acquired pneumonia: Etiologic agents Birth to 20 day Group B streptococci Gram-negative enteric bacilli Cytomegalovirus Listeria monocytogenes Viruses 3 weeks to 3 months Chlamydia trachomatis Respiratory syncytial virus Parainfluenza virus Streptococcus pneumoniae Bordetella pertussis Staphylococcus aureus Viruses (metapneumoivrus, adenovirus, influenza virus, rhinovirus, others)
  • Slide 5
  • Pediatric Community-acquired pneumonia: Etiologic agents Prechool Streptocccus pneumoniae Viruses Mycoplasma pneumoniae Staphylococcus aureus (including MRSA) 5 to 15 years Mycoplasma pneumoniae Chlamydophila pneumoniae Streptocccus pneumoniae Viruses Staphylococcus aureus (including MRSA) Remember to consider tuberculosis, endemic fungal disease (histoplamosis), aspiration pneumonitis, Pneumocystis jiroveci, pertussis, CMV, and other etiologic agents in certain age groups and in specific clinical settings!
  • Slide 6
  • Childhood pneumonia: clinical features Suggestive of Mycoplasma pneumoniae Older children Multiple organ systems may also be involved Rapid and progressive disease in sickle cell anemia Suggestive of Chlamydia trachomatis (in young infant): Afebrile pneumonia with tachypnea and crackles May be associated with conjunctivitis, FTT
  • Slide 7
  • Diagnosis of pediatric pneumonia Bacteria - WBC count & leukocytosis,blood cultures (3%-11% in pneumonia), CRP, ESR; sputum (Gram stain and culture), urine pneumococcal antigen (good sensitivity, poor specificity) Viral - viral isolation, antigen detection, molecular diagnostics, serology limited. Mycoplasma serology (IgM has poor specificity ~60%), paired serology, PCR (limited sensitivity in children; poor sputum sample) Chlamydophila Serology (poor sensitivity, limited specificity in children), Legionella Urinary antigen (sensitivity ~80%, specificity ~100%) Radiology to follow.
  • Slide 8
  • we have found that studies assessing the diagnostic accuracy of clinical, radiological, and laboratory tests for bacterial childhood pneumonia have used a heterogeneous group of gold standards, and found, at least in part because of this, the index tests have widely different accuracies. These findings highlight the need for identifying a widely accepted gold standard for diagnosis of bacterial pneumonia in children. Lynch T, et al. A systematic review on the diagnosis of pediatric bacterial pneumonia: When gold is bronze. Plos ONE 2010; 5(8): e11989. doi:10.1371/journal.pone.0011989
  • Slide 9
  • Michelow IC, et al. Pediatrics 2004; 113:701-707
  • Slide 10
  • Slide 11
  • Slide 12
  • Slide 13
  • Parenteral empiric antibiotics for inpatient treatment of pediatric pneumonia Remember: Most community-acquired pneumonia in children
  • Slide 14
  • Parenteral empiric antibiotics for inpatient treatment of pediatric pneumonia Age groupEmpiric regimen >4 months Bacterial (not Mycoplasma orAmpicillin 150-200 mg/kg/d div qid. or Chlamydophila pneumoniae)Cefuroxime (100-150 mg/kg/d in three divided doses [Max 4-6 g/d), or Ceftriaxone (50-75 mg/kg once daily [MAX 4 gm/d]), or Cefotaxime (150-200 mg/kg/d in three or four divided doses [MAX 8-10g/d]) Mycoplasma or C. pneumoniaeErythromycin (40 mg/kg/d in four divided doses [MAX 4g/d]), or Azithromycin (5 mg/kg once per day [MAX 500 mg/d]), or Doxycycline 4 mg/kg/d in two divided doses [MAX 200 mg/d]) in children >8 years
  • Slide 15
  • Treatment of severe community-acquired bacterial pneumonia Suspect MRSA in: Patients with severe pneumonia, particularly during influenza season, in patients with cavitary infiltrates, and in those with a history of MRSA infection Treatment: Vancomycin or linezolid should be used in such patients Med Lett Drugs Ther 2007; 49(1266):62-64
  • Slide 16
  • Empiric antibiotics for treatment of severe pneumonia Moderately severe (non-ICU) pneumonia: Erythromycin, or azithromycin, or doxycycline PLUS Ceftriaxone or cefotaxime Complicated pneumonia/abscess/effusion or severely ill patients requiring ICU admission: Ceftriaxone or cefotaxime PLUS Vancomycin (trough levels 15-20 ug/mL) or ? clindamycin PLUS Azithromycin PLUS (if necessary) Nafcillin
  • Slide 17
  • Duration of therapy in pediatric pneumonia Few evidence-based data to guide duration of therapy Parenteral: Generally preferable to switch to oral antimicrobial therapy in patients who have received IV medications if (a) afebrile for 24-48 hours and (b) able to keep food down. Uncomplicated cases: 7-10 days combined IV/PO for routine pathogens in uncomplicated infection. Consider continuing PO therapy until one week beyond resolution of fever Complicated cases: Necrotizing pneumonia or abscess likely 4 weeks and patient improving.
  • Slide 18
  • Su-Ting T, Tancredi D. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010; 125:26-33.
  • Slide 19
  • Byington CL, et al. J Clin Microbiol 2010; 48: 520-525
  • Slide 20
  • Parapneumonic effusion and empyema in children organisms Streptococcus pneumoniae most common pathogen Penicillin-susceptible Penicillin non-susceptible Pneumococcal-conjugate vaccine impact Staphylococcus aureus Methicillin-resistant (MRSA) Methicillin-susceptible Group A streptococcus (Streptococcus pyogenes ), others (in immunocompromised, neonates) R/O non-infectious etiologies Critical laboratory evaluation: pleural fluid analysis, other microbial analyses, blood cultures, other testing dependent on clinical scenario
  • Slide 21
  • Antibiotic therapy in therapy in complicated pediatric pneumonia a, parapneumonic effusion and empyema Ceftriaxone (50 to 100 mg/kg once daily [MAX 4 g/day]) or cefotaxime (150 to 200 mg/kg per day in three to four divided doses [MAX 8 to 10 g/day]) PLUS Clindamycin (30 to 40 mg/kg per day in three or four divided doses [MAX 1 to 2 g/day]) OR, for patients very ill and suspect MRSA or allergic to clindamycin Vancomycin (60 mg/kg per day in four divided doses [MAX 2 to 4 g/day]) Might need to cover atypical pathogens in some cases. Modify antibiotic therapy based on culture/microbiologic results when available. a necrotizing process
  • Slide 22
  • Effective Therapy for Serious Infections Caused by MRSA Vancomycin Glycopeptide antibiotic Inhibits bacterial cell wall synthesis by high-affinity binding to cell wall precursors. Therapeutic blood level monitoring VISA, VRSA IV preparation only Linezolid Oxazolidinone antibiotic Interferes with formation of bacterial ribosomal initiation complex to prevent activation of protein synthesis. Available in both intravenous and oral preparations Expensive
  • Slide 23
  • Vancomycin Clinical Failure Rates in MRSA Infections n = 63 patients with MRSA treated with vancomycin Moise-Broder et al. Clin Infect Dis 2004; 38:1700-05

Search related